Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis)

N/A

Report date: 2022/01/19 17:58:03

Base Information

Drug NameAnti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis)
Drug Alias NameJEZ-567
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionInterleukin-3 receptor subunit alpha inhibitorsImmunologic cytotoxicityT lymphocyte replacements
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A